SOM 230 / Pasireotide

DRUG2 trials

Sponsors

NYU Langone Health

Conditions

Atypical Ductal Breast HyperplasiaAtypical Lobular Hyperplasia (ALH) of BreastDuctal Carcinoma in SituLobular Carcinoma in Situ (LCIS)

Phase 1

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial

CompletedNCT01372644

NYU Langone HealthAtypical Ductal Breast Hyperplasia, Atypical Lobular Hyperplasia (ALH) of Breast, Lobular Carcinoma in Situ (LCIS)

Start: 2007-11-30End: 2013-11-30Updated: 2016-12-05

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor

TerminatedNCT01372618

NYU Langone HealthDuctal Carcinoma in Situ

Start: 2011-06-30End: 2015-10-31Updated: 2017-12-27

Related Papers

Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial.

2014-11-1115 citations